Skip to content
Screener

Pre-Tax Income at other companies

Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%
Amgen logo
AmgenAMGN
$2.77B+76.5%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$113.38M-192%
Arrowhead Research logo
Arrowhead ResearchARWR
-$137.57M-137%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$12.79M-83.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$122.09M+9.5%

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income561113
Non-cash interest expense on liabilities for sales of future royalties(22)(14)(43)(28)
Other income1212
Loss before income taxes(91)(114)(275)(264)
Provision for income taxes(1)(1)(2)(2)
Net loss$(92)$(115)$(277)$(266)
Net loss per share, basic and diluted$(0.90)$(1.17)$(2.73)$(2.73)
Shares used in computing net loss per share, basic and diluted101.998.5101.397.4

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's pre-tax income?
Ultragenyx Pharmaceutical (RARE) reported pre-tax income of -$91M in Q2 2026.
How has Ultragenyx Pharmaceutical's pre-tax income changed year-over-year?
Ultragenyx Pharmaceutical's pre-tax income increased by 20.2% year-over-year, from -$114M to -$91M.
What is the long-term trend for Ultragenyx Pharmaceutical's pre-tax income?
Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's pre-tax income has grown at a 6.0% compound annual growth rate (CAGR), from -$452.98M to -$571.23M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Ultragenyx Pharmaceutical's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude